Affordable Access

deepdyve-link
Publisher Website

Gene therapy and cell therapy for the management of radiation damages to healthy tissues: Rationale and early results.

Authors
  • Khalifa, J1
  • François, S2
  • Rancoule, C3
  • Riccobono, D2
  • Magné, N3
  • Drouet, M2
  • Chargari, C4
  • 1 Départment de radiothérapie, institut Claudius-Regaud, institut universitaire du cancer de Toulouse - Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France. Electronic address: [email protected] , (France)
  • 2 Institut de recherche biomédicale des armées, BP73, 91223 Brétigny-sur-Orge cedex, France. , (France)
  • 3 Département de radiothérapie, institut de cancérologie de la Loire Lucien-Neuwirth, 108 bis, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France; Laboratoire de radiobiologie cellulaire et moléculaire, UMR 5822, institut de physique nucléaire de Lyon (IPNL), 69622 Villeurbanne, France; UMR 5822, CNRS, domaine scientifique de la Doua, 4, rue Enrico-Fermi, 69622 Villeurbanne cedex, France; UMR 5822, université Lyon 1, domaine scientifique de la Doua, 4, rue Enrico-Fermi, 69622 Villeurbanne cedex, France; UMR 5822, université de Lyon, domaine scientifique de la Doua, 4, rue Enrico-Fermi, 69622 Villeurbanne cedex, France. , (France)
  • 4 Institut de recherche biomédicale des armées, BP73, 91223 Brétigny-sur-Orge cedex, France; Service de santé des armées, école du Val-de-Grâce, 74, boulevard de Port-Royal, 75005 Paris, France; Département de radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vailant, 94805 Villejuif, France. , (France)
Type
Published Article
Journal
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
Publication Date
Sep 01, 2019
Volume
23
Issue
5
Pages
449–465
Identifiers
DOI: 10.1016/j.canrad.2019.06.002
PMID: 31400956
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Nowadays, ionizing radiations have numerous applications, especially in medicine for diagnosis and therapy. Pharmacological radioprotection aims at increasing detoxification of free radicals. Radiomitigation aims at improving survival and proliferation of damaged cells. Both strategies are essential research area, as non-contained radiation can lead to harmful effects. Some advances allowing the comprehension of normal tissue injury mechanisms, and the discovery of related predictive biomarkers, have led to developing several highly promising radioprotector or radiomitigator drugs. Next to these drugs, a growing interest does exist for biotherapy in this field, including gene therapy and cell therapy through mesenchymal stem cells. In this review article, we provide an overview of the management of radiation damages to healthy tissues via gene or cell therapy in the context of radiotherapy. The early management aims at preventing the occurrence of these damages before exposure or just after exposure. The late management offers promises in the reversion of constituted late damages following irradiation. Copyright © 2019. Published by Elsevier Masson SAS.

Report this publication

Statistics

Seen <100 times